<abstract xmlns="http://www.w3.org/1999/xhtml"><sec id="j_raon-2020-0027_s_005_w2aab3b7c76b1b6b1aab1c16b1Aa"><h3>Background</h3><p>Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma. Its efficacy in randomised controlled trials was demonstrated in patients with well-preserved liver function and good functional status. In the real-world setting, treatment is often offered to patients outside these criteria. We therefore performed a single-centre real-world cohort study on the efficacy of sorafenib in patients with hepatocellular carcinoma.</p></sec><sec id="j_raon-2020-0027_s_006_w2aab3b7c76b1b6b1aab1c16b2Aa"><h3>Patients and methods</h3><p>We identified all patients with hepatocellular carcinoma initiating treatment with sorafenib between January 2015 and January 2018. The primary endpoint was overall survival (OS) since starting sorafenib. Clinical and demographic variables associated with survival were studied.</p></sec><sec id="j_raon-2020-0027_s_007_w2aab3b7c76b1b6b1aab1c16b3Aa"><h3>Results</h3><p>The median OS was 13.4 months (95% CI 8.2–18.6). Multivariable Cox’s regression identified worse ECOG performance status (HR 2.21; 95% CI 1.56–3.16; <italic>P</italic> &lt; 0.0001), Child-Pugh class C (HR 52.4; 95% CI 3.20–859; <italic>P</italic> = 0.005) and absence of prior locoregional treatment (HR 2.30; 95% CI 1.37–3.86; <italic>P</italic> = 0.002) to be associated with increased mortality.</p></sec><sec id="j_raon-2020-0027_s_008_w2aab3b7c76b1b6b1aab1c16b4Aa"><h3>Conclusions</h3><p>Careful selection of patients for treatment with sorafenib is of paramount importance to optimize outcomes.</p></sec></abstract>

BackgroundSorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma. Its efficacy in randomised controlled trials was demonstrated in patients with well-preserved liver function and good functional status. In the real-world setting, treatment is often offered to patients outside these criteria. We therefore performed a single-centre real-world cohort study on the efficacy of sorafenib in patients with hepatocellular carcinoma.Patients and methodsWe identified all patients with hepatocellular carcinoma initiating treatment with sorafenib between January 2015 and January 2018. The primary endpoint was overall survival (OS) since starting sorafenib. Clinical and demographic variables associated with survival were studied.ResultsThe median OS was 13.4 months (95% CI 8.2–18.6). Multivariable Cox’s regression identified worse ECOG performance status (HR 2.21; 95% CI 1.56–3.16; P < 0.0001), Child-Pugh class C (HR 52.4; 95% CI 3.20–859; P = 0.005) and absence of prior locoregional treatment (HR 2.30; 95% CI 1.37–3.86; P = 0.002) to be associated with increased mortality.ConclusionsCareful selection of patients for treatment with sorafenib is of paramount importance to optimize outcomes.

Sorafenib for the treatment of hepatocellular carcinoma: a single-centre real-world study

Radiology and Oncology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

BackgroundSorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma. Its efficacy in randomised controlled trials was...

Sorafenib for the treatment of hepatocellular carcinoma: a single-centre real-world study

Article Category: Research Article

Data publikacji: 28 maj 2020

Zakres stron: 233 - 236

Otrzymano: 18 lis 2019

Przyjęty: 01 gru 2019

DOI: https://doi.org/10.2478/raon-2020-0027

© 2020 Jurij Hanzel, Tajda Kosir Bozic, Borut Stabuc, Rado Jansa, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.